Literature DB >> 24745925

Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants.

Lorenzo Ghiadoni1, Stefano Taddei, Agostino Virdis.   

Abstract

Hypertension and atrial fibrillation are the most common cardiovascular risk factors and clinically significant arrhythmia, respectively. These conditions frequently coexist and their prevalence increases rapidly with aging. Despite several different risk factors and clinical conditions predisposing to hypertension for its high prevalence in the population is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes at the level of left ventricle and or atrium, neurohormonal activation, arterial stiffness, etc.) can contribute to the onset of atrial fibrillation. Some antihypertensive treatments have been shown to contribute to reduce the risk of new-onset atrial fibrillation. Atrial fibrillation is a major risk factor for stroke, which is further increased in the presence of hypertension. For this reason, hypertension is included as a major risk factor in the available models for the risk stratification and the prevention of thromboembolism in patients with atrial fibrillation. In this article we will review the relationship between atrial fibrillation and hypertension, looking at the possible specific indications of the antithrombotic treatment with new classes of anticoagulants in the prevention of thromboembolic events in hypertensive patients with atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24745925     DOI: 10.2174/1381612820666140417100251

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Atrial Fibrillation in Hypertension: Patients' Characteristics.

Authors:  Styliani Koutsaki; Ioannis Koutelekos; Georgia Gerogianni; Maria Koutsaki; Aggeliki Koukouzeli; Georgia Fouka; Maria Polikandrioti
Journal:  Mater Sociomed       Date:  2018-03

2.  A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project.

Authors:  Domingo Orozco-Beltran; Jose A Quesada; Vicente Bertomeu-Gonzalez; Jose M Lobos-Bejarano; Jorge Navarro-Perez; Vicente F Gil-Guillen; Luis Garcia Ortiz; Adriana Lopez-Pineda; Angel Castellanos-Rodriguez; Angela Lopez-Domenech; Antonio Francisco J Cardona-Llorens; Concepcion Carratala-Munuera
Journal:  Sci Rep       Date:  2020-03-16       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.